Climb Bio, Inc. (ELYM)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Ask a question about Climb Bio, Inc. (ELYM)
Company Performance

Current Price

as of Oct 18, 2024

$5.02

P/E Ratio

N/A

Market Cap

$336.64M

Description

Climb Bio, Inc. operates as a clinical-stage biotechnology company. It develops therapeutics for patients with immune-mediated diseases. Its lead product candidate, budoprutug, is an anti-CD19 antibody designed for a broad range of B-cell mediated diseases. The company was founded by Andrew D. Levin and Valerie Morisset on October 18, 2018 and is headquartered in Wellesley Hills, MA.

Metrics

Overview

  • HQWellesley Hills, MA
  • SectorHealth Technology
  • IndustryBiotechnology
  • TickerELYM
  • Price$5.02+3.29%

Trading Information

  • Market Cap$336.64M
  • Float77.39%
  • Average Daily Volume (1m)836,247
  • Average Daily Volume (3m)528,587
  • EPS-$2.15

Company

  • RevenueN/A
  • Rev Growth (1yr)N/A
  • Net Income-$54.89M
  • Gross MarginN/A
  • EBITDA MarginN/A
  • EBITDA-$4.71M
  • EV-$7.25M
  • EV/RevenueN/A
  • P/EN/A
  • P/SN/A
  • P/B1.51
Documents